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Abstract Amyloid-ß (Aß) precursor protein (APP) metab-
olism engages neuronal endolysosomal pathways for Aß
processing and secretion. In Alzheimer’s disease (AD),
dysregulation of APP leads to excess Aß and neuronal
dysfunction; suggesting that neuronal APP/Aß trafficking
can be targeted for therapeutic gain. Cathepsin B (CatB) is
a lysosomal cysteine protease that can lower Aß levels.
However, whether CatB-modulation of Aß improves learn-
ing and memory function deficits in AD is not known. To
this end, progenitor neurons were infected with recombi-
nant adenovirus expressing CatB and recovered cell ly-
sates subjected to proteomic analyses. The results demon-
strated Lamp1 deregulation and linkages between CatB
and the neuronal phagosome network. Hippocampal injec-
tions of adeno-associated virus expressing CatB reduced
Aß levels, increased Lamp1 and improved learning and
memory. The findings were associated with the emergence
of c-fos + cells. The results support the idea that CatB can
speed Aß metabolism through lysosomal pathways and as
such reduce AD-associated memory deficits.
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GFP Green fluorescent protein
CysB Cystatin B
SWATH-MS Sequential window acquisition of all
theoretical fragment ion spectra - mass
spectrometry
PANTHER Protein Analysis Through Evolutionary
Relationships
KEGG Kyoto Encyclopedia of Genes and Genomes
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
GFAP Glial fibrillary acidic protein
Iba1 Ionized calcium binding adaptor molecule 1
Lamp1 Lysosome-associated membrane protein-1
GCL Granular cell layer
DG Dentate gyrus
RAWM Radial arm water maze
Electronic supplementary material The online version of this article
(doi:10.1007/s11481-016-9721-6) contains supplementary material,
which is available to authorized users.
* Howard E Gendelman
hegendel@unmc.edu
1 Department of Pharmacology and Experimental Neuroscience,
University of Nebraska Medical Center, Omaha, NE, USA
2 Department of Internal Medicine, University of Nebraska Medical





Alzheimer’s disease (AD) is the most common form of cog-
nitive impairment affecting the elderly (Selkoe 1991). There is
neither a cure nor an effective therapy for slowing this pro-
gressive neurodegenerative disorder or in targeting the neuro-
pathological disease hallmarks. Prominent characteristics of
the disease include the formation of extracellular amyloid-ß
(Aß) plaques, intraneuronal Aß accumulation and the neuro-
fibrillary tangles known to cause neuronal death and linked
memory impairments (Mattson 2004; Billings et al. 2005;
Oakley et al. 2006). Developing these accumulations begins
with Aß precursor protein (APP) processing. APP is internal-
ized and sorted within endosomes, where APP is processed to
generate Aß. Aß is subsequently degraded by the
endolysosomal pathway, or released into the extracellular
space by fusion of multivesicular bodies with the plasma
membrane. This is but one operative mechanism for Aß-me-
diated AD pathogenesis that is linked to the production of
exosomes, beginning the aggregation process (Rajendran
et al. 2006; Rajendran and Annaert 2012; Pacheco-Quinto
and Eckman 2013). In the AD aged brains, chronic inflamma-
tion contributes to aberrant Aß clearance and aggregation
(Krs t i c and Knuese l 2013) . A l t e r a t i ons in the
endolysosomal/autophagosomal pathways, responsible for
APP/Aß trafficking and degradation, are likely a driving
mechanism involved in this protein dysregulation process
(Rajendran and Annaert 2012). Dysregulation of these path-
ways can accelerate AD pathology. This occurs through a
buildup of nondegraded proteins, leakage of lysosomal con-
tents and apoptosis (Tung et al. 2012). APP processing can
occur within accumulated compartments withmore Aß42 spe-
cies produced compared to less toxic forms of the Aß protein
(Tung et al. 2012). In all, endolysomal/autophagosomal dys-
functions result in intraneuronal Aß accumulation that leads to
synaptic dysfunction and cognitive impairment (Oddo et al.
2003; Knobloch et al. 2007). These all suggest that targeting
neuronal APP/Aß trafficking underlies neuronal survival in
the diseased brain and may improve clinical outcomes.
Cathepsin B (CatB), a lysosomal cysteine protease, medi-
ates proteolysis within lysosomes (Alvarez et al. 2012). In
general, it plays a number of roles in phagocytosis and au-
tophagy, growth/tumor cell proliferation, angiogenesis, inva-
sion, and metastasis (Mort and Buttle 1997; Aggarwal and
Sloane 2014). In regard to AD, abundant CatB immunoreac-
tivity is operative extracellular to and within neuronal
perikarya. It is also associated within senile plaques as seen
in the postmortem AD brains (Cataldo et al. 1990). CatB pres-
ent in the plaques is extracellular to lysosomal dense bodies
and lipofuscin granules. Plaque formation is likely a result of
lysosomal protease-mediated APP processing present in
degenerating neurons (Cataldo and Nixon 1990). In support
of such observations are studies seeking to attenuate CatB
expression in AD. These experiments were performed in an-
imal models demonstrating that pharmacological or gene
CatB inhibition results in reduced ß-amyloidosis and improve-
ments in memory function (Hook et al. 2007; Hook et al.
2008; Hook et al. 2009; Hook et al. 2011; Kindy et al.
2012). Not withstanding, recent studies reported conflicting
results. In these studies CatB was found less expressed in
patients with dementia and CatB deletion by its inhibitors
increased Aß levels (Wang et al. 2012; Tiribuzi et al. 2014).
In such works, overexpression of CatB lowered Aß levels
(Mueller-Steiner et al. 2006; Yang et al. 2011; Wang et al.
2012). As CatB is involved in c-terminal truncation and as
such Aß clearance (Mueller-Steiner et al. 2006; Butler et al.
2011) the findings suggests that it plays a beneficial role in AD
progression. With such conflicting results, it is imperative that
the mechanisms behind Aß clearance and the role played by
CatB overexpression on learning and memory function
are unraveled.
Thus, we sought to directly address the effects of CatB on
Aß production. Our approach was to use recombinant adeno-
virus (Ad) expressing HA-tagged human CatB (Ad-CatB) to
unravel CatB-mediated protein modulation. These studies
were completed in neural progenitor cell (NPC)-derived neu-
rons to ensure homogenous selective cell cultures. To further
explore mechanisms we employed proteomics assays to vali-
date cell-based influences of neuronal function. Concurrently,
adeno-associated virus (AAV) serotype 2/1 recombinant ex-
pressing the CatB (AAV-CatB) was employed to uncover
Bputative^ learning and memory deficits as seen in an AD
animal model of human disease. APP/presenilin-1 (PS1)
double-transgenic (Tg) mice (APP/PS1 mice) received intra-
cranial AAV injections with subsequent studies of behavioral,
neuropathological, and biochemical analyses. The data dem-
onstrated clear associations between CatB and lowered levels
of amyloidogenesis and improvements in learning and behav-
ioral functions. The results lay the groundwork for new ther-
apeutic testing and developments in a disease with few treat-
ment options.
Materials and Methods
Neural Progenitor Cell (NPC) Cultivation
NPCs were prepared using the NeuroCult Proliferation Kit
(StemCell Technologies, Vancouver, BC, Canada) according
to manufacturer’s instruction. In brief, mouse cortices were
dissected at embryonic day 14 and meninges were removed
in ice-cold PBS with 2% glucose. The cortices were mechan-
ically dissociated, filtered with a 40 μm-cell strainer and cul-
tured as neurospheres for 3–5 days in NeuroCult Proliferation
media with epidermal growth factor (20 ng/ml). The
neurospheres were collected and dissociated to single cells
using a NeuroCult Chemical Dissociation Kit (StemCell
Technologies, Vancouver, BC, Canada). The cells were seed-
ed into poly-D-lysine (100 μg/ml) and laminin (15 μg/ml;
Sigma-Aldrich, St. Louis, MO)-coated tissue culture plates.
Proliferation media were exchanged with Neurobasal media
containing B-27 supplement and 1 x penicillin/streptomycin
for differentiation.
Recombinant Adenovirus Generation and Infections
Recombinant Ad expressing cystatin B (AdCysB) and
AdCatB (both co-expressing GFP) were generated using
AdEasy™ XL Adenoviral Vector System (#240010),
pShuttle-IRES-hrGFP-1 vector (#240081) and pShuttle-
IRES-hrGFP-2 vector (#240082, all from Agilent
Technologies, Santa Clara, CA, USA) according to manufac-
turer’s instruction. A PCR fragment containing CysB was
amplified using the primers: Fw: 5′- TACGATTTAGGTGA
CACTATAG -3′ (SP6), Rev.: 5′-TTTCCTCGAGGAAA
TAGGTCAGCTCATC -3′ and pCMV-SPORT6 containing
human CysB coding sequence (Open Biosystems clone
2900656) as a template DNA, digested with Eco RV and
Xho I and inserted into the multiple cloning site (MCS) of
pShuttle-IRES-hrGFP-1. A PCR fragment containing CatB
was amplified using the primers: Fw: 5′- GGATCTAG
GATCCGGCTTCCAAC -3 ′, Rev.: 5 ′- GATCCTCG
AGGATCTTTTCCCAGTACTG -3′ and pCMV-SPORT6
containing human CatB coding sequence (Open Biosystems
clone 30334082) as a template DNA, digested with Bam HI
and Xho I and inserted into the MCS of pShuttle-IRES-
hrGFP-2 to generate pShuttle-CatBHA-IRES-hrGFP-2.
Recombinant AdGFP and AdAPPsw (co-expressing GFP)
were generated as previously described (Kiyota et al.
2015b). Viral titer was measured using AdEasy™ Viral Titer
Kit (#972500, Agilent Technologies, Santa Clara, CA, USA).
Differentiated NPCs were infected with adenoviruses
(MOI = 10 per each) in 200 μl fresh Opti-MEM (Life
Technologies, Carlsbad, CA, USA) for 1 h, followed by wash-
ing with PBS and 1-day incubation in Neurobasal media. The
media were subjected to Aß40 or Aß42 ELISA (Life
Technologies, Carlsbad, CA, USA) according to manufac-
turer’s instruction. Cell lysates were prepared and subjected
to immunoblot and proteomic analyses.
Quantitative Proteomics by SWATH-MS
NPCs were seeded at a density of 4.0 × 105 per well in a
24-well plate and differentiated with neurobasal media for
24 h prior to further treatment. Cells were infected with
AdGFP or AdCatB as described above. At the 72-h post
infection time point, cells were washed 3 times with ice-
cold PBS, then lysed on ice with 100 μl of 2% (w/v) SDS
in 100 mM Tris-HCL, pH 7.6, supplemented with protease
and phosphatase inhibitors (final concentration 1×; Thermo
Fisher Scientific, Waltham, MA, USA) per well. Lysate was
collected in 1.7 ml sterile microcentrifuge tubes, pipetting
repeatedly to further breakdown cellular components, kept
on ice. 0.5 μl benzonase (Millipore, Darmstadt, Germany)
was added per tube to breakdown DNA and to make the lysate
solution less viscous. Lysate was thoroughly mixed by pipet
and vortexed shortly before being spun down at 10,000 g for
10 min at 4 °C to pellet and remove cellular debris.
Supernatant was transferred into a new sterile 1.7 ml tube,
flash frozen on dry ice, and stored at −80 °C until proceeding
with proteomic analysis.
Protein concentration was determined using a BCA kit
(Thermo Fisher Scientific, Waltham, MA, USA) following
the manufacturer’s instructions. Prior to digestion, DTT was
added to cell lysates for a final concentration of 25 mM and
samples were heated at 95 °C for 5 min. Samples were
allowed to cool and were processed as previously described
(Haverland et al. 2014; Arainga et al. 2015) using filter aided
sample preparation (FASP) digestion of 50 μg per sample.
Following overnight digestion, samples were cleaned using
Oasis MCX column (Waters Corporation, Milford, MA,
USA), followed by C18 Zip-Tips (Thermo Fisher Scientific).
Cleaned peptides were quantitated using NanoDrop2000 by
A205.
Following resuspension, 1 μg of sample was used for
SWATH-MS analysis as previously described (Haverland
et al. 2014). Briefly, 1μg of each sample was injected through
Eksigent cHiPLC column (75 μm× 15 cmChromXP C18-CL
3 μm 120 Å) onto 5600 TripleTOF (Sciex) using a typical
gradient 2–60% ACN in 60 min. Experimental samples used
for SWATH were spiked with HRM calibration peptides
(Biognosys AG) for retention time correction during data
analysis and data was acquired using Data-Independent
Acquisition. Samples for the library were acquired using
Data Dependent Acquisition (DDA) and all files searched
together using ProteinPilot 4.2 Uniprot_SwissProt database
(2014) for one output. Protein Pilot identified 1242 proteins
at 1% FDR Global Fit confidence and these proteins were
imported into PeakView (Sciex) software for SWATH
processing.
Raw data was transformed by natural log (ln) and z-scores,
z-test and z-p values were computed per treatment condition,
as previously described (Cheadle et al. 2003; Haverland et al.
2014). Z-test and associated p-values were computed using a
standard normal distribution. Bioinformatics tools were used
to discern relationships between proteins found significantly
different (p < 0.05), specifically between AdCatB and AdGFP,
as well as AdCatB and control conditions. UniProt IDs were
entered into the Protein Analysis Through Evolutionary
Relationships (PANTHER) classification system and
the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analys is to determine major
pathways affected by treatment. The proteins changed
within an identified major pathway were colored pink
and cyan for up- and down-regulation respectively in-
dicating positively identified proteins.
AAV Generation
A PCR fragment containing 3× HA was amplified using the
primers: Fw: 5′- CTCACGGGGATTTCCAAGTC -3′, Rev.:
5′- GCCTAAGCTTAGGCGTAGTCAGGTACAT -3′ and
pShuttle-IRES-hrGFP-2 as a template DNA, digested with
Nhe I and Hind III and inserted into the MCS of pAAV2-
CBA-MCS-WPRE (AAV2 inverted terminal repeats flanking
cytomegalovirus immediate early enhancer, chicken ß-actin
promoter with first exon and intron sequences, MCS,
Woodchuck hepatitis post-transcriptional regulatory element,
and the bovine growth hormone polyadenylation site (Kiyota
et al. 2011) to construct pAAV2-CBA-MCS-HA-WPRE. To
construct pAAV2-CatB, a PCR fragment containing CatB as
described above was digested with Bam HI and Xho I and
inserted into the MCS of pAAV2-CBA-MCS-HA-WPRE.
AAV-GFP was generated using a pGFP vector (Klein et al.
2002; Kiyota et al. 2010). AAV-293 cells (#240073, Agilent
Technologies, Santa Clara, CA, USA) were co-transfected
with cis plasmid pAAV2-CatB or pGFP, an AAV1 trans plas-
mid p5E18RXC1 and a helper plasmid pAdΔF6 (obtained
from University of Pennsylvania Gene Therapy Program) to
produce AAVs. Cells were harvested, AAVswere purified and
titration performed (Kiyota et al. 2009, 2011 #31).
AAV Transduction
Differentiated NPCs seeded at a density of 400,000 cells (24-
well) were transduced with AAVs in 200 μl Neurobasal me-
dia, then 300 μl fresh media were added 24 h after transduc-
tion. Cells were harvested using ice-cold RIPA buffer
(Thermo Fisher Scientific,Waltham,MA, USA) with protease
inhibitor cocktail (Sigma, St. Louis, MO, USA) 3 days after
AAV transduction. Protein concentrations were determined
using a Micro BCA Protein Assay (Thermo Fisher
Scientific, Waltham, MA, USA).
3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium
Bromide (MTT) Assay
Differentiated NPCs were seeded at a density of 50,000 cells
(96-well) were transduced with indicated amounts of AAVs in
50 μl Neurobasal media for 24 h, then 50 μl fresh media were
added. Three days after transduction cells were incubated with
10 μl of MTT (ATCC® 30-1010 K) for 4 h at 37 °C. Media
were aspirated from each well and 50μl of dimethyl sulfoxide
was added to dissolve the formazan crystals, and absorbance
was measured using a plate reader at 570 nm.
Transgenic Mice
APP/PS1 double-transgenic mice were bred as previously de-
scribed (Kiyota et al. 2011). Age-matched non-Tg mice in B6/
129 F1 strain (Jackson laboratory, Bar Harbor, ME, USA)
were maintained by intercrossing in the same facility. All an-
imal work performed in this study adhered to the guidelines
established by the Institutional Animal Care and Use
Committee at University of Nebraska Medical Center.
Stereotaxic Injection
Mice at 3 months of age received i.p. injection of ketamine/
xylazine anesthesia (100 mg/kg ketamine and 20 mg/kg
xylazine). After mice were immobilized in a stereotaxic mi-
croinjection frame (Stoelting, Wood Dale, IL, USA), a linear
skin incision was made exposing the bregma, and a 1-mm burr
hole was drilled in the skull 2.1 mm posterior and 1.8 mm
lateral to the bregma on both sides using a hand-held driller
(Craftsman). A total volume of 2 μl of saline containing AAVs
(1 × 109 vg) was injected into hippocampus using Hamilton
syringe (Hamilton, Reno, NV, USA) equipped with a 30-gauge
needle at 0.2 μl/min at a depth of 1.8 mm below the skull.
Tissue Preparation
Four months post-injection, mice were deeply euthanized with
isoflurane and transcardially perfused with 25 ml of ice-cold
PBS, followed by 4% PFA/PBS (Sigma-Aldrich). The brains
were rapidly removed. The left hemisphere was dissected and
immediately frozen in dry ice for biochemical testing. The
right hemisphere was immersed in freshly depolymerized
4% paraformaldehyde for 48 h at 4 °C, and protected by suc-
cessive 24-h immersions in 15% and 30% sucrose in 1 x PBS.
Fixed, cryopreserved brains were sectioned coronally using a
Cryostat (Leica, Bannockburn, IL, USA)with sections serially
collected and stored at −80 °C for immunohistochemical tests.
For biochemical testing, protein extraction of an extracellular-
enriched fraction was extracted as described (Lesne et al.
2006). After separation of extracellular-enriched fraction, pro-
tein pellet was homogenized in ice-cold RIPA buffer (Thermo
Fisher Scientific, Waltham, MA, USA) with protease inhibitor
cocktail (Sigma, St. Louis, MO, USA). Protein concentration
was determined using Micro BCA Protein Assay (Thermo
Fisher Scientific, Waltham, MA, USA).
Immunoblots
Protein lysates were diluted 1:1 with Laemmli buffer contain-
ing ß-mercaptoethanol, incubated at 100 °C for 5 min, elec-
trophoresed on 10% SDS-polyacrylamide tris-tricine gels or
tris-glycine gels, and electroblotted to 0.45-μm pore size
PVDF membranes (Immobilon-P, Millipore, Billerica, MA,
USA). Membranes were blocked in 5% skim milk/TBST, and
incubated with Aß monoclonal (6E10, 1:1000, Covance,
Emeryville, CA, USA), GFP rabbit polyclonal (1:5000,
Abcam, Cambridge, MA, USA), Flag monoclonal (M2,
1:5000, Sigma, St. Louis, MO, USA), HA monoclonal (HA-
7, 1:5000, Sigma, St. Louis, MO, USA) or Lamp1 rabbit
polyclonal (1:1000, ab24170, Abcam, Cambridge, MA,
USA) at 4 °C for overnight, followed by 30-min incubation
in 5% skim milk/TBST with HRP-conjugated anti-mouse or
rabbit IgG antibodies (Ab) (1: 2000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Immunoreactive
bands were detected with SuperSignal West Pico or Femto
Chemiluminescent substrate (Thermo Fisher Scientific,
Waltham, MA, USA) and captured using a FluorChem M
MultiFluor system (ProteinSimple, Santa Clara, CA, USA)
or a myECL Imager (Thermo Fisher Scientific, Waltham,
MA, USA). After detection of the bands, membranes were
incubated with Restore Western Blot Stripping Buffer
(Thermo Fisher Scientific, Waltham, MA, USA) and were
then used to detect ß-actin for normalization using HRP-
conjugated anti-ß-actin monoclonal (1: 5000, Sigma, St.
Louis, MO, USA). For quantitative analysis, ImageJ software
(NIH, Bethesda, MD, USA) was used to quantify band inten-
sities relative to control on captured images.
Immunofluorescence
Immunofluorescence was performed using specific Abs to
Lamp1 (1:1000, ab24170, Abcam, Cambridge, MA, USA)
and HA (HA-7, 1:5000, Sigma, St. Louis, MO, USA). Alexa
Fluor 488 goat anti-mouse IgG and Alexa Fluor 568 goat anti-
rabbit IgG (Life Technologies, Carlsbad, CA, USA) were used
as secondary. Images were captured using a 63X oil lens on a
LSM 710 confocal microscope (Carl Zeiss Microimaging
Inc., Thornwood, NY, USA). Images were quantified as oc-
cupied areas per cell bodies using ImageJ software (NIH,
Bethesda, MD, USA).
Immunohistochemistry
Immunohistochemistry was performed as described (Kiyota
et al. 2011) using specific Abs to identify glial fibrillary acidic
protein (GFAP, rabbit polyclonal, 1:2000, DAKO,
Carpenteria, CA, USA), ionized calcium binding adaptor mol-
ecule 1 (Iba1, rabbit polyclonal, 1:1000, Wako, Richmond,
VA, USA), pan-Aß (rabbit polyclonal, 1:100, Zymed, San
Francisco, CA, USA) and c-fos (rabbit polyclonal, 1:5000,
Calbiochem, Gibbstown, NJ, USA). Immunodetection was
visualized using biotin-conjugated anti-rabbit IgG was used
as a secondary Ab, followed by a tertiary incubation with
Vectastain ABC Elite kit (Vector Laboratories, Burlingame,
CA, USA). The areas of Aß loads were analyzed by ImageJ
software (NIH, Bethesda, MD, USA) at 300 μm intervals in
twelve 30 μm coronal sections from each mouse. Seven
mouse brains per group were analyzed.
Stereological Quantification
We defined cells with nuclei that were DAB stained in the
granular cell layer (GCL) of the dentate gyrus (DG) as c-
fos + cells (Kiyota et al. 2015a). Positive cells were count-
ed in a blinded fashion in every 8th section through the
entire anterio–posterior extent of the DG (total 12 sections
per hippocampus) and estimated using stereological analy-
sis with Stereo Investigator system with an optical frac-
tionator module (MBF Bioscicence, Williston, VT). The
system consisted of a high sensitivity digital camera
(OrcaFlash2.8, Hamamatsu C11440-10C, Hamamatsu,
Japan) interfaced with a Nikon Eclipse 90i microscope
(Nikon, Melville, NY, USA). Within the Stereo
Investigator program, the contour of DG of each section
was delineated using a tracing function. While sections
showed shrinkage along the anterio–posterior axis, the ex-
tent of shrinkage between different animals was similar.
The dimensions for the counting frame (450 × 450 um)
and the grid size (500 × 500 um) were set. The z-plane
focus was adjusted at each section for clarity, and images
were automatically acquired according to each setting. The
data file containing all slice pictures were quantified by
the fractionator and marked positive cells in the analyzed
areas of the DG that were observed in each counting
frame. Based on these parameters and marked cell counts,
the Stereo Investigator program computed the estimated
cell population. These total markers, cell counts and the
Gunderson (m = 1) values were recorded for each animal
and compared between groups using a statistical software
(Prism 4.0, Graphpad Software, San Diego, CA).
Radial Arm Water Maze Test
The radial arm water maze (RAWM) task was run as
described (Kiyota et al. 2013). Animals were introduced
into the perimeter of a circular water-filled tank (21–
22 °C) 110 cm in diameter and 91 cm in height (San
Diego Instruments, San Diego, CA) with triangular inserts
placed in the tank to produce six swim paths radiating
from a central area. Spatial cues for mouse orientation
were present on the tank walls. At the end of one arm,
a 10 cm circular plexiglass platform was submerged 1 cm
deep and as such hidden from the mice. The platform was
located in the same arm for four consecutive acquisition
trials (T1 through T4), and one 30-min delayed retention
trial (T5), but in a different arm on different days. For T1-
T4, the mouse started the task from a different randomly
chosen arm, excluding the arm with the platform. After
four trials, the mouse was returned to its cage for
30 min, and then administered the retention trial (T5)
starting from the same arm as in T4. Each trial lasted
1 min and an error was scored each time when the mouse,
excluding tail, entered the wrong arm, entered the arm
with the platform but did not climb on it, or did not make
a choice for 20 s. The trial ended when the mouse
climbed onto and remained on the hidden platform for
10 s. The mouse was given 20 s to rest on the platform
between trials. After each trial, mice were gently wiped
using paper towels to remove aqueous droplet then put
back into cages on a warming pad. The errors over 9-
day test were divided into three blocks, and the errors in
each block consisting of 3-day test were averaged for
statistical analysis.
Statistics
All data were normally distributed and presented as mean
values ± standard errors of the mean (SEM). In case of
single mean comparison, data were analyzed by Student’s t-
test. In case of multiple mean comparisons, the data were
analyzed by one-way ANOVA and Newman-Keuls post-hoc
or two-way repeated measures ANOVA, followed by
Bonferroni multiple comparison tests using statistics software
(Prism 4.0, Graphpad Software, San Diego, CA). A value of
p < 0.05 was regarded as significant.
Results
CatB Suppresses NPC-Derived Neuronal Aß Production
CatB is known to decrease Aß concentrations by cleavage of
Aß into smaller fragments (Mueller-Steiner et al. 2006). To
confirm and extend these results CatB-mediated modulation
of Aß was investigated in NPC-derived neurons infected with
Ad expressing GFP (AdGFP), human APP Swedish mutant
(AdAPPsw) or co-infected with AdAPPsw and AdGFP,
AdCatB or Ad expressing Flag-tagged cystatin B (AdCysB:
an endogenous CatB inhibitor and a positive control for Aß
aggregation (Ceru et al. 2010; Smajlovic et al. 2011).
Conditioned media were subjected to Aß40 or Aß42-specific
ELISA, showing that CatB significantly reduced production
of Aß40 (44.6% of control, Fig. 1a) and Aß42 (32.1% of
control, Fig. 1b) from the neurons, and Aß42/Aß40 ration
(71.6% of control, Fig. 1c). To examine Aß retention in neu-
rons, cell lysates were subjected to immunoblot assays using
Aß antibody (Fig. 1d). CysB enhanced Aß protein expression
as seen by increased intensity band through a wide range of
molecular weights, suggesting it promoted aggregation.
Opposingly, CatB facilitated Aß degradation and inhibited
its production in neurons.
Proteomics Analyses of AdCatB-Infected Neurons
The molecular mechanisms underlying CatB-mediated Aß
degradation are unclear yet. To this end, we applied quan-
titative SWATH-MS proteomics to uncover proteins affect-
ed by CatB overexpress ion in NPC- neurons
(Supplementary Data S1A). Upon comparison with
AdGFP-infected control and with uninfected control, over-
all quantitative profiling identified 543 proteins that were
significantly changed with CatB overexpression, as
assessed by paired-samples z-scores (Supplementary Data
S1B). Up- and down-regulated proteins in AdCatB-
infected neurons were 49.4 and 50.6% of total (n = 268
and 275, respectively). A total of 320 out of 543 proteins
were altered with 164 up- and 156 down-regulated in
Fig. 1 CatB suppresses Aß production from mouse NPC-derived
neurons. a, b NPC-derived neurons were infected with AdAPPsw or
co-infected with AdAPPsw and AdGFP, AdCysB or AdCatB. Aß40 (a)
or Aß42 (b) production was quantified, and Aß42/Aß40 ration c was
calculated. d Aß retention in neurons was examined using 6E10
antibody (top). Expression of CatB (HA-tagged CatB), CysB (Flag-
tagged CysB) and GFP were to validate experimental condition
(bottom). Bars represent mean ± S.E.M. *p < 0.05, **p < 0.01,
***p < 0.001, one-way ANOVA, Newman-Keuls post hoc test
AdCatB treated cells in comparison with both AdGFP-
infected and uninfected controls (Fig. 2a, Supplementary
Data S1C). The biological functions of the identified pro-
t e in s were as s e s sed by PANTHER (F ig . 2b ,
Supplementary Data S1D). This was done as a multiface-
ted bioinformatic approach focused on analyzing altered
biological processes, demonstrating that CatB overexpres-
sion had effects on a number of intracellular pathways,
particularly those related to endolysosomal, phagosomal,
and mitochondrial functions. Protein enrichment engaged
in specific metabolic processes. Expansion of this family
of proteins identified primary metabolic processes as a
major altered cellular function (Fig. 2b, Supplementary
Data S1E). Further investigation of these pathways utiliz-
ing the KEGG database showed that proteins within
endolysosomal compartments such as Lamp1 and
vATPase were up-regulated, indicating that CatB overex-
pression is involved in phagosome neuronal networks
(Fig. 2c).
AAV-Mediated CatB Expression
To assess CatB over-expression in an AD mouse model,
AAV-CatB was generated. To examine AAV-CatB effi-
cacy, NPC-derived neurons were transduced with AAV-
GFP and AAV-CatB. Immunoblot analyses showed that
the differential transduction of GFP and CatB were sub-
sequently increased in a dose-dependent manner
(Fig. 3a). To assess CatB neuronal effects, cell viability
was measured using the MTT assay. AAV transduction
Fig. 2 Proteomics changes induced by AdCatB. a Heatmap of 320
proteins that were significantly altered with AdCatB administration,
common to both the AdGFP and untreated controls, indicating a near
even amount of up- (164 proteins) and down- (156 proteins) regulation.
b PANTHER analysis revealed enrichment of proteins involved in
metabolic process. Expansion of this family of proteins identified
primary metabolic processes as the major influencing subgroup, and a
further expansion yielded protein metabolic processes as a primary
enriched metabolic function with AdCatB treatment. c KEGG pathway
analysis revealed that LAMP1 and vATPase, involved in the phagosomal
compartments were significantly altered with AdCatB treatment as
compared to AdGFP treated and untreated controls
of CatB did not alter cell viability when compared to
control GFP groups (Fig. 3b). These results demonstrat-
ed high-level expression of CatB without neurotoxicity.
CatB Attenuates Hippocampal Aß Levels in APP/PS1
Mice
To elucidate the effect of CatB on ß-amyloidosis we injected
AAV-GFP or -CatB (1 × 109 vg/2 μl/shot) bilaterally into the
hippocampus of three month-old APP/PS1 mice. Following
animal sacrifice at seven months of age brains were secured.
GFP and CatB expression in the hippocampus were confirmed
at the terminal time point (Fig. 3c). Fluorescent analyses
showed that efficient GFP expression was observed in the
hippocampus injected with AAV-GFP, notably in pyramidal
neurons and neuropils in Cornet d’Ammon (CA) 1 and the
DG of the hippocampus. HA-immune-positive cells express-
ing exogenous CatB were observed in the AAV-CatB injected
hippocampus, but not in AAV-GFP. At the time point expres-
sion of GFAP (astrocyte marker) or IbaI (microglial marker) is
unchanged between the groups in APP/PS1 mice, demonstrat-
ing that CatB-overexpression does not induce astro/
microgliosis (Fig. 3d-f). Neuropathological analyses for Aß
(Fig. 4a) demonstrated that the AAV-CatB-injected group
showed significant reductions in hippocampal Aß loads
(23.2% reduction when compared to AAV-GFP group,
Fig. 4b). To quantify the levels of Aß40 and Aß42, hippocam-
pal homogenates were processed to separate extracellular-
enriched fraction (extracellular Aß plaques) and intracellular-
enriched fraction. Aß ELISA showed decreased Aß40 and
Aß42 levels in both (extracellular Aß – 39.6% and 38.8%
reduction for Aß40 and Aß42, intracellular levels – 40.2%
and 27.4% reduction for Aß40 and Aß42, respectively when
compared to AAV-GFP group, Fig. 4c). These data suggest
that CatB attenuates ß-amyloidosis in the hippocampus.
CatB Enhances Lamp1 Expression in Brain Tissues
and in Neurons
To investigate the proteome of cells transduced by AAV-CatB
intracellular fractions of hippocampal proteins were subjected
to immunoblot assays (Fig. 5a). CatB overexpression in-
creased Lamp1 levels by 68.0% when compared to the
AAV- GFP-injected mouse group (Fig. 5b). To validate the
results in cultured neurons, AAV-transduced cells were immu-
nostained with an antibody to Lamp1 (Fig. 5c). Quantification
Fig. 3 Optimization for AAV-GFP and CatB in vitro. a Immunoblots
show expression of GFP and CatB in a dose-dependent manner in
NPC-derived neurons transduced with AAVs at 1 × 107–9 vg/10,000
cells/well. b Overexpression of CatB in NPC-derived neurons has no
effect on cell viability as compared to control (Con) or GFP group. c
Hippocampal frozen sections were immunostained for HA to identify
exogenous CatB expression. HA-immunostaining and GFP fluorescent
images in the AAV-GFP or CatB-injected hippocampus were shown.
Scale bar =100 μm (50 μm in high magnified images). d Hippocampal
frozen sections were immunostained for GFAP (astrocyte) or Iba1
(microglia). Scale bar =200 μm. e Quantification of GFAP-positive
cells in the hippocampus. f Quantification of Iba-positive cells in the
hippocampus
on confocal microscopical images demonstrated that Lamp1
expression was enhanced in soma of neurons treated with
AAV-CatB (60.3% increase to control, Fig. 5d). These data
indicated that CatB induces the lysosomal activity.
CatB Restores Spatial Learning and Memory
To assess if AAV-CatB transduction effects learning andmem-
ory, we employed a RAWM task to assess memory acquisition
and retention. These tests were performed in non-Tg, APP/
PS1, and AAV-injected APP/PS1 mice. Three 3-day blocks
for trial 1 (T1; randomized initial trial), T4 (final acquisition
trial), and T5 (delayed retention trial) were used to evaluate
the memory function at 6–7 months of age (Fig. 6a) (Kiyota
et al. 2013). All animal groups showed reduced error numbers
by T4 through three blocks. While the average number in non-
Tgwas lower than that in others at the third block, AAV-CatB-
injected APP/PS1 mice showed lower number of errors with
significant differences as compared to uninjected or AAV-
GFP-injected APP/PS1 mice by T5. These results support
our prior findings that APP/PS1 mice show impaired hippo-
campal function, memory acquisition and retention. The
changes occurs by 6–7 months of age and were shown previ-
ously by RAWM tests (Diamond et al. 1999; Arendash et al.
2001; Kiyota et al. 2011; Kiyota et al. 2013). Improvements in
APP/PS1 animals injected with AAV-CatB showed lower
number of functional errors.
The proto-oncogene c-fos is one of the immediate-early
genes that are induced by neural activity and behavior, and
known to play a role in the neuroplastic mechanisms for mem-
ory consolidation (Palop et al. 2003; Kiyota et al. 2011). To
address if memory improvement in AAV-CatB-injected APP/
Fig. 4 CatB attenuates Aß loads
in the hippocampus of APP/PS1
mice. a Representative images of
Aß staining in the hippocampus
of AAV-GFP and AAV-CatB-
injected APP/PS1 mice at
7 months of age. Scale bar
=200 μm. b Quantification of
total Aß loads in the hippocampal
region (n = 7 per group, 12
sections per brain). c The levels of
Aß40 and Aß42 in extracellular
and intracellular-enriched
fractions were measured by
human Aß40 or Aß42-specific
ELISA (n = 5). Bars represent
mean ± S.E.M. *p < 0.05, one-
way ANOVA, Newman-Keuls
post hoc test
PS1 mice were associated with c-fos expression, the numbers
of c-fos-immunoreactive (c-fos+) neurons were evaluated in
the granular cell layer (GCL) of the DG (Fig. 6b). While the
number of c-fos+ neurons in both uninjected and AAV-GFP-
injected APP/PS1 mice was reduced compared to nonTg con-
trol (57.7% and 49.8% reduction, respectively), the numbers
in AAV-CatB-injected APP/PS1 mice were similar to that in
non-Tg controls (56.9% and 67.4% increase of uninjected and
AAV-GFP-injected APP/PS1 mice, respectively) (Fig. 6c).
These data suggest that CatB treatment can recover learning
and memory functions.
Discussion
Aß induces neuroinflammation with consequent synaptic and
neuritic injury, and tau hyperphosphorylation. These process-
es eventually lead to neuronal death and memory impairment
and are characteristic of the pathobiology of AD (Mattson
2004; Billings et al. 2005; Oakley et al. 2006). Based on these
observations, therapeutic efforts have largely been made
through targeting Aß. As seen over the past decade break-
down of toxic Aß accumulation remains a major target to
ameliorate disease. Such targeting strategies have been fo-
cused on Aß removal by both active and passive Aß immuni-
zation. Notably, Aß clearance is associated with improved
memory function in AD mouse models (Huang and Mucke
2012). Nonetheless, clinical trials employing such immuniza-
tion strategies thus far have shown disappointing result.
Untoward immunological responses and more limited im-
provement in clinical symptoms with worsened disease out-
comes were reported following immunizations (Lemere 2013;
Panza et al. 2014). This suggests that removing Aß, particu-
larly extracellular deposits, may not yield improvements in
disease outcomes. Hence the outcomes are likely due to con-
tinuous Aß production in the AD brains. Targeting lysosomal
degradation pathways to affect APP/Aß trafficking, specifical-
ly leading to degradation and clearance of Aß within neurons
is a likely promising approach to slow the pathological pro-
gression of human disease (Kiyota et al. 2015b).
As CatB functions in protein degradation during phagocy-
tosis or autophagy (Alvarez et al. 2012) harnessing this protein
as a therapeutic agent and notably by affecting LAMP1 regu-
lation is a realistic mechanism forward towards developing a
novel disease treatment strategy. In the human brain, CatB is
expressed in glial and in endothelial cells of vascularised
Fig. 5 AAV-mediated CatB
transduction increases Lamp1
expression in the hippocampus of
APP/PS1 mice and cultured
neurons. a Immunoblot of Lamp1
in intracellular fraction of the
mouse hippocampus. b
Quantification of Lamp1
expression (n = 6). c Confocal
microscopy shows cellular
localization of Lamp1 lysosomal
compartment (red) in neurons. d
Lamp1 expression levels were
quantified using ImageJ (n = 3).
Bars represent mean ± S.E.M.
*p < 0.05, **p < 0.01, one-way
ANOVA, Newman-Keuls post
hoc test
glioblastomas, and serves as a predictor of shorter survival in
brain tumors (Levicar et al. 2003). In the current study over-
expression of neuronal CatB did not affect cell viability. In
addition, no changes in astrocyte or microglial responses were
seen. This highlights that CatB-overexpression elicits no un-
toward effects due to neuron-specific transduction of AAV
(Kiyota et al. 2009). As aforementioned abundant CatB is
expressed in neuronal perikarya as well as extracellularly as-
sociated within senile plaques in the postmortem brain of AD
patients (Cataldo et al. 1990), and lysosomal protease-
mediated APP processing in degenerating neurons is consid-
ered to develop the plaques (Cataldo and Nixon 1990). Hence
reduction in CatB expression or genetic deficiency of CatB
decreases Aß levels and improved memory function in rodent
models of AD (Hook et al. 2007; Hook et al. 2008; Hook et al.
2009; Hook et al. 2011; Kindy et al. 2012). On the one hand,
overexpression of CatB also lowers Aß levels (Mueller-
Steiner et al. 2006; Yang et al. 2011; Wang et al. 2012).
Morevoer, we now show that cognitive function was im-
proved by AAV-CatB treatments in our AD mouse model.
This was shown by performance in the RAWM task and fur-
ther confirmed by immunohistological analysis, suggesting a
possible therapeutic approach for compensation of lower ex-
pression of CatB in AD patients with more profound dementia
(Tiribuzi et al. 2014).
Treatment with CatB lead to a variety of changes in the
neuronal proteome with particular focus on cell-associated
phagosomal and mitochondrial pathways. Dysregulation of
the endolysosomal and autophagosomal pathways is a sig-
nificant contributing factor in the aggregation of Aß, pos-
sibly by both contributing to the genesis of toxic,
aggregation-prone Aß subspecies and by lack of degrada-
tion and ultimately causing lysosomal leakage. Lysosomal
function is tied closely with its acidic pH, with an optimal
pH of 4.5–5.0. Such acidification is tightly regulated by the
lysosomal membrane and its proteins, including LAMP1
and V-ATPase (Shen and Mizushima 2014). Both, interest-
ingly, were found to be significantly upregulated in CatB-
expressed neurons. The lysosomal V-ATPase complex
senses contents of the lysosomal and controls the acidifica-
tion of the lumen, contributing to degradation. This sug-
gests the mechanism behind the degradation of Aß, as
shown by a general decrease in Aß40 and Aß42 levels in
ELISA analysis, is directly related to lysosomal function.
Conclusion
Overall, we now demonstrate that recombinant CatB overex-
pression results in reduced Aß production in both cultured
neurons and AD mouse model brains. AAV-CatB injection
ameliorates AD pathobiology including ß-amyloidosis and
impairments in learning and memory in the mouse brain.
These effects are caused by promoting lysosomal degradation,
specifically related to Aß metabolism. Taken together, these
findings support the idea that CatB has therapeutic potential
for ameliorating the signs and symptoms of AD.
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